PRESS RELEASE published on 12/09/2025 at 14:50, 11 months 2 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 1 year ago Medincell élargit le rôle du Dr Grace Kim pour stimuler la croissance du capital américain Biotechnologie Medincell Stratégie Pharmaceutique Dr Grace Kim Croissance Du Capital Américain
BRIEF published on 11/11/2025 at 08:05, 1 year ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 1 year ago Informations privilégiées / Autres communiqués Medincell nomme le Dr Grace Kim au poste de Chief Strategy Officer, U.S. Finance, pour renforcer la croissance de son capital aux États-Unis. Découvrez son parcours et son rôle clé chez Medincell Croissance Chief Strategy Officer Medincell Dr Grace Kim Capital Américain
PRESS RELEASE published on 11/11/2025 at 08:00, 1 year ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 1 year ago Croissance continue pour Medincell et nouvelles perspectives avec l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 11/05/2025 at 13:51, 1 year ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 1 year ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
PRESS RELEASE published on 11/05/2025 at 13:46, 1 year ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 10/10/2025 at 22:16, 1 year 1 month ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
Published on 11/11/2026 at 19:31, 1 hour 56 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 4 hours 57 minutes ago ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:00, 7 hours 27 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 7 hours 27 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 19:29, 1 hour 58 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 2 hours 45 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 3 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 3 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 3 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 3 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
